UA81050C2 - Use of 2h[1,3]-oxazino[3, 2-a]indole derivatives for the treatment of neuropathic pain - Google Patents

Use of 2h[1,3]-oxazino[3, 2-a]indole derivatives for the treatment of neuropathic pain Download PDF

Info

Publication number: UA81050C2
Authority: UA; Ukraine
Prior art keywords: compound; neuropathic pain; treatment; formula; pain
Prior art date: 2003-07-18

Application number

UAA200600306A

Other languages

English (en)

Ukrainian (uk)

Inventor

Angelo Guglielmotti

Lorenzo Polenzani

Alessandra Alisi

Nicola Cazzolla

Original Assignee

Aziende Chimische Riunite Ange

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-18

Filing date

2004-08-07

Publication date

2007-11-26

2004-08-07 Application filed by Aziende Chimische Riunite Ange filed Critical Aziende Chimische Riunite Ange

2007-11-26 Publication of UA81050C2 publication Critical patent/UA81050C2/uk

Links

208000004296 neuralgia Diseases 0.000 title claims abstract description 18
208000021722 neuropathic pain Diseases 0.000 title claims abstract description 16
KGVOXAQTJVXNNV-UHFFFAOYSA-N 2h-[1,3]oxazino[3,2-a]indole Chemical class C1=CC=C2N(C=CCO3)C3=CC2=C1 KGVOXAQTJVXNNV-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 26
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
150000007522 mineralic acids Chemical class 0.000 claims abstract description 7
150000007524 organic acids Chemical class 0.000 claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 7
125000000217 alkyl group Chemical group 0.000 claims abstract description 6
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 5
238000002360 preparation method Methods 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 2
230000000996 additive effect Effects 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
239000002253 acid Substances 0.000 abstract description 5
208000004454 Hyperalgesia Diseases 0.000 description 11
241000700159 Rattus Species 0.000 description 11
241001465754 Metazoa Species 0.000 description 8
208000002193 Pain Diseases 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
208000000114 Pain Threshold Diseases 0.000 description 6
206010053552 allodynia Diseases 0.000 description 6
230000037040 pain threshold Effects 0.000 description 6
210000003497 sciatic nerve Anatomy 0.000 description 6
208000000094 Chronic Pain Diseases 0.000 description 5
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 5
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
229960001052 streptozocin Drugs 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000282412 Homo Species 0.000 description 3
208000035154 Hyperesthesia Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
210000000548 hind-foot Anatomy 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
208000032131 Diabetic Neuropathies Diseases 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
230000002641 glycemic effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
201000001119 neuropathy Diseases 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
230000036407 pain Effects 0.000 description 2
230000037324 pain perception Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
206010044652 trigeminal neuralgia Diseases 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000012387 aerosolization Methods 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
229940076309 dihydrate dibasic calcium phosphate Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
-1 indole compound Chemical class 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000002483 medication Methods 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

UAA200600306A 2003-07-18 2004-08-07 Use of 2h[1,3]-oxazino[3, 2-a]indole derivatives for the treatment of neuropathic pain UA81050C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT001467A ITMI20031467A1 (it)	2003-07-18	2003-07-18	Farmaco attivo nel dolore neuropatico
PCT/EP2004/007633 WO2005014001A1 (en)	2003-07-18	2004-07-08	Use of 2h- [1, 3] - oxazino [3, 2-a] indole derivatives for the treatment of neuropathic pain

Publications (1)

Publication Number	Publication Date
UA81050C2 true UA81050C2 (en)	2007-11-26

Family

ID=34131193

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200600306A UA81050C2 (en)	2003-07-18	2004-08-07	Use of 2h[1,3]-oxazino[3, 2-a]indole derivatives for the treatment of neuropathic pain

Country Status (21)

Country	Link
US (1)	US20060211691A1 (ja)
EP (1)	EP1646391B1 (ja)
JP (1)	JP2006528142A (ja)
KR (1)	KR20060033784A (ja)
CN (1)	CN100409850C (ja)
AR (1)	AR045993A1 (ja)
AT (1)	ATE345137T1 (ja)
AU (1)	AU2004262876B2 (ja)
CA (1)	CA2526852C (ja)
DE (1)	DE602004003252T2 (ja)
DK (1)	DK1646391T3 (ja)
EA (1)	EA008927B1 (ja)
ES (1)	ES2276317T3 (ja)
GE (1)	GEP20084307B (ja)
HK (1)	HK1087027A1 (ja)
IL (1)	IL172156A0 (ja)
IT (1)	ITMI20031467A1 (ja)
PL (1)	PL1646391T3 (ja)
PT (1)	PT1646391E (ja)
UA (1)	UA81050C2 (ja)
WO (1)	WO2005014001A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101563075B (zh) *	2006-12-26	2011-09-28	大鹏药品工业株式会社	糖尿病性神经病治疗剂
DE102007058504A1 (de)	2007-12-05	2009-07-09	Acino Ag	Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5189041A (en) *	1990-11-16	1993-02-23	Syntex (U.S.A.) Inc.	Tricyclic 5-ht3 receptor antagonists
GB9120628D0 (en) *	1991-09-27	1991-11-06	Fujisawa Pharmaceutical Co	Pyrrolobenzoxazine derivatives and process for preparation thereof
HU219121B (hu) *	1992-03-12	2001-02-28	Smithkline Beecham Plc.	Kondenzált indolszármazékok, eljárás előállításukra és ezeket tartalmazó 5-HT4-receptor antagonista hatású gyógyászati készítmények
IL117438A (en) *	1995-03-16	2001-12-23	Lilly Co Eli	Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JP2003506388A (ja) *	1999-08-04	2003-02-18	アイカゲンインコーポレイテッド	疼痛および不安症を処置または予防するための方法
US20040038874A1 (en) *	2002-08-22	2004-02-26	Osemwota Omoigui	Method of treatment of persistent pain

2003
- 2003-07-18 IT IT001467A patent/ITMI20031467A1/it unknown
2004
- 2004-07-08 KR KR1020067000490A patent/KR20060033784A/ko active IP Right Grant
- 2004-07-08 CN CNB2004800172642A patent/CN100409850C/zh not_active Expired - Fee Related
- 2004-07-08 DK DK04740899T patent/DK1646391T3/da active
- 2004-07-08 PT PT04740899T patent/PT1646391E/pt unknown
- 2004-07-08 CA CA2526852A patent/CA2526852C/en not_active Expired - Fee Related
- 2004-07-08 GE GEAP20049233A patent/GEP20084307B/en unknown
- 2004-07-08 WO PCT/EP2004/007633 patent/WO2005014001A1/en active IP Right Grant
- 2004-07-08 DE DE602004003252T patent/DE602004003252T2/de not_active Expired - Lifetime
- 2004-07-08 AT AT04740899T patent/ATE345137T1/de active
- 2004-07-08 US US10/560,836 patent/US20060211691A1/en not_active Abandoned
- 2004-07-08 EP EP04740899A patent/EP1646391B1/en not_active Expired - Lifetime
- 2004-07-08 PL PL04740899T patent/PL1646391T3/pl unknown
- 2004-07-08 EA EA200600270A patent/EA008927B1/ru not_active IP Right Cessation
- 2004-07-08 JP JP2006520721A patent/JP2006528142A/ja active Pending
- 2004-07-08 ES ES04740899T patent/ES2276317T3/es not_active Expired - Lifetime
- 2004-07-08 AU AU2004262876A patent/AU2004262876B2/en not_active Ceased
- 2004-07-15 AR ARP040102486A patent/AR045993A1/es not_active Application Discontinuation
- 2004-08-07 UA UAA200600306A patent/UA81050C2/uk unknown
2005
- 2005-11-24 IL IL172156A patent/IL172156A0/en not_active IP Right Cessation
2006
- 2006-06-28 HK HK06107281A patent/HK1087027A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
US20060211691A1 (en)	2006-09-21
DK1646391T3 (da)	2007-03-19
ATE345137T1 (de)	2006-12-15
EA008927B1 (ru)	2007-08-31
HK1087027A1 (en)	2006-10-06
KR20060033784A (ko)	2006-04-19
AU2004262876B2 (en)	2010-05-20
JP2006528142A (ja)	2006-12-14
EA200600270A1 (ru)	2006-06-30
ITMI20031467A1 (it)	2005-01-19
IL172156A0 (en)	2006-04-10
EP1646391A1 (en)	2006-04-19
CN100409850C (zh)	2008-08-13
PT1646391E (pt)	2007-01-31
CN1809361A (zh)	2006-07-26
AU2004262876A1 (en)	2005-02-17
DE602004003252T2 (de)	2007-05-03
ES2276317T3 (es)	2007-06-16
CA2526852C (en)	2011-08-30
PL1646391T3 (pl)	2007-04-30
GEP20084307B (en)	2008-02-11
DE602004003252D1 (de)	2006-12-28
WO2005014001A1 (en)	2005-02-17
EP1646391B1 (en)	2006-11-15
CA2526852A1 (en)	2005-02-17
AR045993A1 (es)	2005-11-23
WO2005014001A9 (en)	2005-05-26

Publication	Publication Date	Title
RU2340342C2 (ru)	2008-12-10	СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
JP2010511616A (ja)	2010-04-15	水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法
SK287714B6 (en)	2011-07-06	Use of amino acid derivative for the preparation of pharmaceutical compositions for treating phantom pain or diabetic neuropathic pain
SK287539B6 (sk)	2011-01-04	Použitie peptidovej zlúčeniny na prípravu farmaceutického prostriedku na liečenie bolesti
EP1035851B1 (de)	2001-08-16	Endothelin-rezeptorantagonisten zur bekämpfung von hyperlipidämie
WO2000044359A2 (de)	2000-08-03	Verwendung von thiadiazolderivaten zur prophylaktischen und therapeutischen behandlung von infektionen
UA81050C2 (en)	2007-11-26	Use of 2h[1,3]-oxazino[3, 2-a]indole derivatives for the treatment of neuropathic pain
EP2150253B1 (fr)	2011-03-30	Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
KR0133555B1 (ko)	1998-04-23	5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
KR101073993B1 (ko)	2011-10-17	신경병증성 통증의 치료를 위한 인다졸 유도체의 용도
JP2022503784A (ja)	2022-01-12	てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
EP2146713B1 (fr)	2011-11-09	Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
MXPA06000677A (es)	2006-12-13	Uso de derivados de 2h-[1,3]-oxazino [3,2-a]indol para el tratamiento de dolor neuropatico
US20200230084A1 (en)	2020-07-23	Methods of treating disease with dichlorphenamide
ES2323981T3 (es)	2009-07-28	Tiazolopirimidinas para uso en terapia.
DE3426220A1 (de)	1986-01-23	Verwendung von o-substituierten brenztraubensaeureoximen zur prophylaxe und/oder behandlung von herz- undkreislauferkrankungen sowie entsprechende arzneimittel